STOCK TITAN

LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

LeonaBio (LONA) reported a third-quarter net loss of $21.164 million while advancing its Phase 3 ELAINE-3 breast cancer trial. The company targets enrollment completion in 4Q 2026 and expects topline data in 2H 2027. The trial tests lasofoxifene with abemaciclib in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer following progression on aromatase inhibitors and CDK4/6 inhibitors.

Cash, cash equivalents and investments fell to $32.3 million at September 30, 2026, from $88.3 million at year-end 2025. Quarterly operating cash use rose to $18.98 million from $4.7 million a year earlier. Research and development expenses reached $15.015 million, versus $2.825 million. Net loss widened from $6.611 million, although loss per share narrowed to $0.89 from $1.68. LeonaBio expects to update proposed Phase 2 timing for ALS candidate brelgometon after ELAINE-3 enrollment finishes.

Loading...
Loading translation...
13 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.ELAINE-3 enrollment completion remains targeted for 4Q 2026, with topline data expected in 2H 2027.
  • Moderate pointTotal liabilities declined to $22.119 million at September 30, 2026, from $64.361 million at year-end 2025.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Lasofoxifene regulatory, manufacturing and commercial readiness activities are advancing to support a potential launch.
  • Minor pointELAINE-1 median progression-free survival was 5.6 months versus 3.7 months with fulvestrant.
  • Minor pointELAINE-1 objective response rates were 13.3% versus 2.9% with fulvestrant.
8 minor points
  • Minor pointELAINE-1 included a complete response lasting more than 2.5 years.
  • Minor pointELAINE-1 treatment was well-tolerated, with patients reporting quality-of-life benefits.
  • Minor pointELAINE-2 combination treatment delivered median progression-free survival of approximately 13 months in heavily pretreated patients.
  • Minor pointELAINE-2 combination treatment achieved an objective response rate of 56%.
  • Minor pointELAINE-2 combination treatment achieved a clinical benefit rate of 65.5%.
  • Minor pointELAINE-2 combination treatment was generally well-tolerated, with most adverse events low grade.
  • Minor pointBrelgometon Phase 1 enrolled 80 healthy volunteers, demonstrating favorable safety and tolerability.
  • Minor pointBrelgometon Phase 1 demonstrated dose-proportional pharmacokinetics and central nervous system penetration, supporting Phase 2 advancement.

Negative

  • Major pointThird-quarter net loss widened to $21.164 million from $6.611 million; loss per share narrowed to $0.89 from $1.68.
  • Moderate pointCash, cash equivalents and investments fell to $32.3 million from $88.3 million at year-end 2025.
  • Moderate pointThird-quarter operating cash use increased to $18.98 million from $4.7 million a year earlier.
  • Moderate pointStockholders' equity fell to $16.017 million at September 30, 2026, from $27.790 million at year-end 2025.
  • Minor pointThird-quarter R&D expenses increased to $15.015 million from $2.825 million a year earlier, primarily from ELAINE-3 spending.
3 minor points
  • Minor pointThird-quarter G&A expenses rose to $6.863 million from $4.049 million, primarily from personnel expenses, including stock-based compensation.
  • Minor pointELAINE-1 was not powered, limiting interpretation of its comparative results.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Proposed brelgometon Phase 2 timing update depends on completion of ELAINE-3 enrollment.

Key Figures

ELAINE-3 enrollment completion: 4Q 2026 ELAINE-3 topline data: 2H 2027 Cash, cash equivalents and investments: $32.3 million +5 more
ELAINE-3 enrollment completion
4Q 2026
Target timing
ELAINE-3 topline data
2H 2027
Expected timing
Cash, cash equivalents and investments
$32.3 million
As of September 30, 2026; compared with $88.3 million at December 31, 2025
Net cash used in operations
$18.98 million
Quarter ended September 30, 2026; compared with $4.7 million in the prior-year quarter
R&D expenses
$14.6 million
Quarter ended September 30, 2026; compared with $2.8 million in the prior-year quarter
G&A expenses
$6.9 million
Quarter ended September 30, 2026; compared with $4.0 million in the prior-year quarter
Net loss
$21.2 million
Quarter ended September 30, 2026; compared with $6.6 million in the prior-year quarter
Net loss per share
$0.89 per share
Quarter ended September 30, 2026; compared with $1.68 per share in the prior-year quarter

Previous Earnings Reports

3 past events · Latest: Aug 14
Same Type 3 events
  1. Aug 14

    Q2 earnings

    24h Move
    -3.2%

    June cash balance and ELAINE-3 enrollment timeline accompanied quarterly financial results.

  2. May 07

    Q1 earnings

    24h Move
    +1.8%

    A $90 million financing and cash balance were reported alongside ELAINE-3 milestones.

  3. Mar 26

    FY2025 earnings

    24h Move
    -7.3%

    The report cited a $90 million private placement and year-end cash balance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

serm, cdk4/6 inhibitor, progression free survival, bicr, +1 more
5 terms
serm medical
"selective estrogen receptor modulator (SERM)"
A SERM, or selective estrogen receptor modulator, is a type of drug that interacts with the body’s estrogen receptors and can either mimic or block estrogen’s effects depending on the tissue—helping bone in one place while blocking breast or uterine effects in another. Investors care because SERM clinical results, regulatory approvals or safety issues can dramatically change a drugmaker’s sales prospects and stock value; think of a SERM as a smart key that opens some doors while keeping others locked, so small changes in how it performs can have big financial impact.
cdk4/6 inhibitor medical
"abemaciclib, a CDK4/6 inhibitor"
A CDK4/6 inhibitor is a type of cancer drug that blocks two proteins (CDK4 and CDK6) that tell cells to divide, effectively slowing or stopping the growth of tumors. Think of it as cutting power to a photocopier that keeps making cancer cells; that control can shrink tumors or delay progression. For investors, these drugs matter because clinical trial results, regulatory approvals, patent life, safety issues and competition directly affect sales potential and company value.
progression free survival medical
"improvement in progression free survival (PFS)"
Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.
bicr medical
"blinded, independent central review (BICR)"
A blinded independent central review (BICR) is an external, neutral assessment of clinical trial results—often scans or other objective measures—performed without knowing which treatment each patient received. For investors, a BICR increases confidence that reported trial benefits or risks aren’t biased; like an impartial referee double-checking a close game, it can affect regulatory approval chances, deal-making, and how the market values a company.
pharmacokinetics medical
"dose-proportional pharmacokinetics and CNS penetration"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027

BOTHELL, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended September 30, 2026, and provided recent pipeline and business updates.

“We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene. Our efforts extend beyond clinical execution as we advance regulatory, manufacturing and commercial readiness activities designed to support a potential launch and maximize the opportunity to bring this important therapy to patients as efficiently as possible.”

“We believe lasofoxifene has the potential to redefine treatment for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, a population that continues to face disease progression despite advances in care. The compelling body of clinical and scientific evidence generated to date, including encouraging efficacy and tolerability findings from our Phase 2 studies, reinforces our confidence in the program and its potential to become a new standard of care.” added Dr. Litton.

Clinical Development & Pipeline Programs

Lasofoxifene – A third generation novel, nonsteroidal selective estrogen receptor modulator (SERM) with a unique binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations commonly associated with resistance to endocrine therapy in metastatic breast cancer.

  • Lasofoxifene is being advanced in ELAINE-3, a Phase 3 clinical trial (NCT05696626), in combination with abemaciclib, a CDK4/6 inhibitor, as a targeted therapy for estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated metastatic breast cancer, following progression on aromatase inhibitors and CDK4/6 inhibitors. The primary endpoint of the study is a statistically significant improvement in progression free survival (PFS), as determined by blinded, independent central review (BICR). ELAINE-3 aims to establish a new standard of care for this genetically defined patient group with limited treatment options.  
  • Lasofoxifene was previously evaluated in two Phase 2 studies in patients with ER+, HER2-negative locally advanced or metastatic breast cancer expressing an ESR1 mutation, ELAINE-1 and ELAINE-2.
    • ELAINE-1, an open-label, randomized trial comparing lasofoxifene to fulvestrant, showed improved outcomes for lasofoxifene as a potential monotherapy. Although the trial was not powered, results included longer median progression-free survival (5.6 vs. 3.7 months), higher objective response rates (13.3% vs. 2.9%) and a durable complete response lasting more than 2.5 years. The treatment was well-tolerated with patients reporting quality-of-life benefits.
    • ELAINE-2, an open-label study evaluating lasofoxifene in combination with abemaciclib, demonstrated clinical benefits in heavily pretreated patients, with a median progression-free survival of approximately 13 months, an objective response rate of 56% and a clinical benefit rate of 65.5%. The combination was generally well-tolerated with most adverse events being low grade.
  • In April 2026, LeonaBio hosted a virtual Key Opinion Leader event with two leading physicians in the breast cancer field to discuss the current and evolving treatment landscape in metastatic breast cancer and the potential for lasofoxifene to transform the standard of care for patients with treatment-resistant ER+, HER2-negative, ESR1-mutated metastatic breast cancer.
    • The event featured a discussion with David Portman, M.D., Chief Executive Officer of Sermonix Pharmaceuticals and an oncology consultant to LeonaBio, along with two physician experts in the breast cancer field. A replay of the event is available on the LeonaBio website under “Events & Presentations” in the “Investor Relations” section here.

Brelgometon (ATH-1105) – A novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. Brelgometon is currently in clinical development for the potential treatment of ALS.  

  • LeonaBio’s first-in-human Phase 1 double-blind, placebo-controlled clinical trial (NCT06432647) enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses of brelgometon, demonstrating a favorable safety and tolerability profile as well as dose-proportional pharmacokinetics and CNS penetration and supporting its advancement into a Phase 2 proof-of-concept trial.
  • The Company expects to provide an update on the timing of a proposed Phase 2 proof-of-concept clinical trial following completion of enrollment of the Phase 3 ELAINE-3 clinical trial as it continues to focus on its lasofoxifene program.

Financial Results

  • Cash Position. Cash, cash equivalents and investments were $32.3 million as of September 30, 2026, compared to $88.3 million as of December 31, 2025. Net cash used in operations was $18.98 million for the quarter ended September 30, 2026, compared to $4.7 million for the quarter ended September 30, 2025.
  • Research and Development (R&D) Expenses. R&D expenses were $14.6 million for the quarter ended September 30, 2026, compared to $2.8 million for the quarter ended September 30, 2025. The increase was driven primarily by clinical trial spend related to the ELAINE-3 trial for lasofoxifene.
  • General and Administrative (G&A) Expenses. G&A expenses were $6.9 million for the quarter ended September 30, 2026, compared to $4.0 million for the quarter ended September 30, 2025. The increase was driven primarily by personnel-related expenses, including stock-based compensation.
  • Net Loss. Net loss was $21.2 million, or $0.89 per share, for the quarter ended September 30, 2026, compared to a net loss of $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025.

About LeonaBio

LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and brelgometon (ATH-1105), are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.

For more information, visit www.leonabio.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: the beneficial characteristics, safety and efficacy of LeonaBio’s drug candidates; the potential of LeonaBio to complete the Phase 3 ELAINE-3 clinical trial for lasofoxifene and to meet the trial endpoints, the potential of ELAINE-3 to serve as a registrational trial, and any subsequent clinical trials to show the clinical benefits of lasofoxifene to the satisfaction of the FDA to support its regulatory approval; the potential of any subsequent clinical trials to show the beneficial characteristics, safety and efficacy of brelgometon; LeonaBio’s drug candidates as potential treatments for metastatic breast cancer, amyotrophic lateral sclerosis and other diseases; LeonaBio’s future development plans and the timing thereof; the potential learnings from preclinical studies and other nonclinical data and their ability to inform and improve future clinical development plans; the markets for LeonaBio’s drug candidates, if approved for commercial use, and LeonaBio’s ability to serve those markets; anticipated development milestone timelines, such as the initiation of clinical trials, the completion of enrollment in the Phase 3 ELAINE-3 clinical trial and the timing of data releases, and LeonaBio’s ability to meet such timelines; LeonaBio’s ability to obtain and maintain regulatory approval of its drug candidates in the United States and other jurisdictions and the timing thereof, and any related restrictions, limitations or warnings in the label of any approved drug candidate; LeonaBio’s regulatory, manufacturing and commercial readiness activities; LeonaBio’s ability to commercialize any approved products; and the sufficiency of LeonaBio’s capital resources to advance both its oncology and neurodegeneration programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” “suggest,” “potential,” “target” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the possible failure to realize certain anticipated benefits of the license relating to lasofoxifene and the recent private placement financing, including with respect to future financial and operating results; the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of LeonaBio’s drug candidates; development of drug candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for drug candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; whether LeonaBio’s trials are sufficiently powered to meet the planned endpoints; LeonaBio may not be able to recruit sufficient patients for its clinical trials or complete enrollment within anticipated timelines; the outcome of legal proceedings that may in the future be instituted against LeonaBio, its directors and officers; possible negative interactions of LeonaBio’s drug candidates with other treatments; FDA regulatory delays and uncertainty and new policies, including executive orders, changes in the leadership of federal agencies such as the FDA and SEC, staff layoffs, budget cuts to agency programs and research and changes in drug pricing controls; LeonaBio’s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets, including as a result of tariffs; the impact of competition; the impact of drug candidate development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in LeonaBio’s filings with the SEC from time to time. These forward-looking statements speak only as of the date hereof and LeonaBio undertakes no obligation to update forward-looking statements. LeonaBio may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Investor & Media Contact:
Julie Rathbun
LeonaBio
julie.rathbun@leonabio.com
206-769-9219


LeonaBio, Inc.
Condensed Consolidated Balance Sheets
(Amounts in thousands)
(unaudited)
  September 30, December 31, 
  2026 2025 
Assets     
Cash and cash equivalents $16,336 $69,276 
Short-term investments  15,974  19,055 
Other short-term assets  4,023  1,127 
Other long-term assets  1,803  2,693 
Total assets $38,136 $92,151 
Liabilities and stockholders' equity     
Current liabilities $7,328 $10,015 
Sermonix pre-funded warrant  —  37,488 
Milestone liability  13,951  15,116 
Long-term liabilities  840  1,742 
Total liabilities  22,119  64,361 
Stockholders' equity  16,017  27,790 
Total liabilities and stockholders' equity $38,136 $92,151 


LeonaBio, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands, except share and per share amounts)
(Unaudited)
  Three Months Ended September 30, 
  2026  2025 
Operating expenses:      
Research and development $15,015  $2,825 
Milestone liability change in fair value  (411)  — 
General and administrative  6,863   4,049 
Total operating expenses  21,467   6,874 
Loss from operations  (21,467)  (6,874)
Other income, net  303   263 
Net loss $(21,164) $(6,611)
Unrealized gain (loss) on available-for-sale securities  (3)  1 
Comprehensive loss attributable to common stockholders $(21,167) $(6,610)
Net loss per share attributable to common stockholders, basic and diluted  (0.89)  (1.68)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted  23,740,719   3,943,887 



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does LeonaBio expect ELAINE-3 enrollment completion and results?

LeonaBio targets ELAINE-3 enrollment completion in 4Q 2026 and expects topline data in 2H 2027. The Phase 3 trial evaluates lasofoxifene combined with abemaciclib in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

What were LeonaBio's third-quarter 2026 net loss and cash position?

LeonaBio reported a $21.164 million net loss, or $0.89 per share, for the quarter ended September 30, 2026, and $32.3 million in cash, cash equivalents and investments at quarter-end. The year-earlier quarterly loss was $6.611 million, or $1.68 per share.

What is the primary endpoint of LeonaBio's ELAINE-3 trial?

ELAINE-3's primary endpoint is a statistically significant improvement in progression-free survival, measured by blinded, independent central review. Progression-free survival measures the time patients remain alive without their cancer worsening.

Keep reading